Biofrontera

Biofrontera EBIT Growth

The Year-over-Year EBIT Growth of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 35.41 %. In the previous year, Year-over-Year EBIT Growth was -133.19 % — a change of -126.59% (higher).

EBIT Growth

35.41 %

YoY

-126.59%

Last updated:

Year-over-Year EBIT Growth of Biofrontera is 2025 35.41 % . Year-over-Year EBIT Growth of Biofrontera was 2024 -133.19 % . It decreases by -126.59% higher compared to the previous year.

The Biofrontera EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-32.61 EUR
Jan 1, 2019
-26.51 EUR
Jan 1, 2020
76.00 EUR
Jan 1, 2021
-529.93 EUR
Jan 1, 2022
104.50 EUR
Jan 1, 2023
200.75 EUR
Jan 1, 2024
-133.19 EUR
Jan 1, 2025
35.41 EUR
The Biofrontera EBIT Growth history
YEAREBIT GrowthYoY
35.41 %-126.59%
-133.19 %-166.34%
200.75 %+92.11%
104.50 %-119.72%
-529.93 %-797.26%
76.00 %-386.66%
-26.51 %-18.70%
-32.61 %+78.22%
-18.30 %+20.95%
-15.13 %+104.73%
-7.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Year-over-Year EBIT Growth of Biofrontera is 35.41 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Biofrontera since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biofrontera

All Key Metrics — Biofrontera